awmsg logo



idelalisib (Zydelig®)


Reference No. 2597

Publication date:
03/04/2017


Appraisal information

idelalisib (Zydelig®) 100 mg film-coated tablet
idelalisib (Zydelig®) 150 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 08/02/2017
AWMSG meeting date: 15/03/2017
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0717
Ministerial ratification: 03/04/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Idelalisib (Zydelig®) is recommended as an option for use as monotherapy for the treatment of adult patients with follicular lymphoma that is refractory to two prior lines of treatment. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download